---
layout: default
title: Adrenaline
parent: 僅模型預測 (L5)
nav_order: 19
evidence_level: L5
indication_count: 0
---

# Adrenaline
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Adrenaline: Drug Repurposing Evaluation — Insufficient Data

## One-Sentence Summary

Adrenaline (epinephrine) is a well-known sympathomimetic amine used broadly in emergency medicine for anaphylaxis, cardiac arrest, and severe asthma. No TxGNN-predicted new indications are currently available for this drug, and the evidence pack contains **no clinical trial data**, **no literature**, and **no regulatory license records** to support a repurposing evaluation at this time.

---

## Quick Overview

| Item | Content |
|------|------|
| Drug (INN) | Adrenaline (Epinephrine) |
| DrugBank ID | Not available |
| Original Indication | Not recorded in this evidence pack |
| Predicted New Indication | None — no TxGNN predictions available |
| TxGNN Prediction Score | N/A |
| Evidence Level | N/A (No prediction to evaluate) |
| Market Status | Not marketed (未上市) |
| Number of Authorizations | 0 |
| Recommended Decision | **Hold** |

---

## Why is This Report Incomplete?

This evidence pack was generated with significant data gaps that prevent a meaningful repurposing evaluation:

1. **No TxGNN predictions**: The `predicted_indications` array is empty. Without a predicted new indication, the core repurposing hypothesis cannot be formulated or assessed.

2. **No DrugBank ID mapped**: Although a DrugBank query returned 1 result, the `drugbank_id` field remains null. This prevents automated retrieval of mechanism of action, pharmacological targets, and safety profile data.

3. **No regulatory records**: The drug shows 0 marketing authorizations and a status of "not marketed" (未上市), meaning there are no local label data (SmPC equivalent) from which to extract indications, warnings, or contraindications.

Currently, detailed mechanism of action data is not available in this evidence pack. Based on general pharmacological knowledge, adrenaline (epinephrine) is an endogenous catecholamine and non-selective adrenergic agonist (acting on α1, α2, β1, and β2 receptors). It is widely used in emergency medicine for anaphylaxis, cardiac arrest, and acute bronchospasm. However, without a specific TxGNN prediction, no mechanistic bridge to a new indication can be evaluated.

---

## Clinical Trial Evidence

Currently no related clinical trials registered in this evidence pack.

---

## Literature Evidence

Currently no related literature available in this evidence pack.

---

## Market Information

No marketing authorizations are recorded for this drug in the current evidence pack. The market status is listed as "not marketed" (未上市) with 0 licenses.

---

## Safety Considerations

> Please refer to the SmPC (Summary of Product Characteristics) or local equivalent prescribing information for safety information. All safety fields in this evidence pack are currently unpopulated.

---

## Data Gaps Identified

The following blocking or high-severity data gaps were flagged during evidence pack assembly:

| ID | Category | Item | Severity | Impact | Remediation |
|----|----------|------|----------|--------|-------------|
| DG001 | Drug Level | Prescribing label warnings/contraindications | **Blocking** | Cannot enter Stage 1 safety screening | Download and parse label PDF from regulatory authority website |
| DG002 | Drug Level | Mechanism of Action (MOA) | **High** | Affects mechanistic relevance analysis | Query DrugBank API with correct identifier |

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
There are no TxGNN-predicted indications for Adrenaline in this evidence pack, and critical data fields (DrugBank ID, MOA, safety profile, regulatory licenses) remain unpopulated. A repurposing evaluation cannot proceed without a target indication to assess.

**To proceed, the following is needed:**
- Resolve the DrugBank ID mapping (DrugBank ID for epinephrine is likely **DB00668**) and re-run the evidence collection pipeline
- Ensure TxGNN prediction pipeline includes Adrenaline/Epinephrine and generates candidate indications
- Obtain prescribing label data (warnings, contraindications, indications) from the relevant regulatory authority
- Re-generate the evidence pack once the above gaps are filled, then re-evaluate

---

*Disclaimer: This report is for research purposes only and does not constitute medical advice. Any drug repurposing candidates require clinical validation before application.*
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

